Anders Lilja

Anders Lilja has extensive work experience in the biotech and pharmaceutical industry. Anders is currently serving as the VP Preclinical R&D at Valneva, starting in January 2023. Prior to Valneva, they worked at HOOKIPA Pharma Inc. from 2014 to 2021, holding various roles including SVP Infectious Diseases, Gewerberechtlicher Geschäftsführer, SVP Technical Development, VP Technical Development, Head of Technical Development, and Project Leader. At HOOKIPA, they were responsible for technical development, clinical assay validation, process development, assay development, and GMP manufacturing. Before HOOKIPA, Anders worked as the Director of Virology & Molecular Biology at Batavia Bioservices from July 2013 to February 2014. Anders also gained research experience at Novartis Vaccines and Diagnostics, where they led a cytomegalovirus vaccine research project and served as an Associate Project Leader and Research Investigator. Anders completed their postdoc at Princeton University from September 2002 to January 2009.

Anders Lilja earned a Ph.D. in Biochemistry from the University of Maryland between 1997 and 2002. Prior to that, they obtained an M.Sc. in Chemical Engineering from Chalmers University of Technology from 1992 to 1996.